yahoo_financeOriginal article
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
Phase 2positiveRezatapoptPositive
AI Analysis
Summary
PMV Pharmaceuticals announced updated interim data from the Phase 2 PYNNACLE pivotal trial showing promising results for rezatapopt monotherapy in ovarian cancer.
Clinical Trial Data
Phase
2
Outcome Details
Updated promising interim monotherapy data
Importance:6/10
Sentiment:
0.70
ovarian cancerrezatapoptPYNNACLE trialmonotherapyPhase 2
Related Companies
Read the original article
Published by yahoo_finance on August 31, 2026 8:01 PM